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Available online 1 July 2016Individuals with bicuspid aortic valves (BAV) are at a higher risk of developing thoracic aortic aneurysms (TAA)
than patientswith trileaﬂet aortic valves (TAV). The aneurysms associatedwith BAVmost commonly involve the
ascending aorta and spare the descending aorta. Smooth muscle cells (SMCs) in the ascending and descending
aorta arise from neural crest (NC) and paraxial mesoderm (PM), respectively. We hypothesized defective differ-
entiation of the neural crest stem cells (NCSCs)-derived SMCs but not paraxial mesoderm cells (PMCs)-derived
SMCs contributes to the aortopathy associated with BAV. When induced pluripotent stem cells (iPSCs) from
BAV/TAA patients were differentiated into NCSC-derived SMCs, these cells demonstrated signiﬁcantly decreased
expression of marker of SMC differentiation (MYH11) and impaired contraction compared to normal control. In
contrast, the PMC-derived SMCswere similar to control cells in these aspects. The NCSC-SMCs from the BAV/TAA
also showed decreased TGF-β signaling based on phosphorylation of SMAD2, and increased mTOR signaling. In-
hibition of mTOR pathway using rapamycin rescued the aberrant differentiation. Our data demonstrates that de-
creased differentiation and contraction of patient's NCSC-derived SMCs may contribute to that aortopathy
associated with BAV.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bicuspid aortic valves (BAV) are the most common congenital car-
diovascular malformation affecting 0.9–2% of the general population
(Michelena et al., 2014; Prakash et al., 2014). BAV account for more
morbidity and mortality than all other cardiovascular congenital
malformations combined. Thoracic aortic aneurysm (TAA) occurs in ap-
proximately 50–70% of patients with BAV which is signiﬁcantly higher
than the rate of TAA formation in patients with tricuspid aortic valves
(TAV) (Fedak et al., 2005). Furthermore, patients with BAV have an
eight-fold higher risk of aortic dissection, which carries very high mor-
tality (Michelena et al., 2011). There are no therapeutic agents to pre-
vent TAA in BAV.
Whether the aneurysms in BAV patients arise due to altered hemo-
dynamic forces from the abnormal valve or from an underlying genetic
defect leading to both BAV and TAA is currently unknown (Prakash et
al., 2014). The assessment of hemodynamic ﬂow in BAV patients
shows distinct differences of the ﬂow patterns compared to TAV pa-
tients (Keane et al., 2000). However, even after aortic valve replacement. This is an open access article underto correct the hemodynamics, some BAV patients still develop an as-
cending aortic aneurysm(Itagaki et al., 2015). Studies using aortic tissue
from BAV patients have shown potential evidence of aortopathy of the
aortic wall, including immature smooth muscle cells (SMCs) (Grewal
et al., 2014b; Nkomo et al., 2003). However, these results failed to delin-
eate between the two possible causes of TAA mentioned above.
Accumulating evidence suggests an inherited component to the eti-
ology of BAV complicated by TAA (BAV/TAA), but the responsible locus
or loci are still largely unknown (Cripe et al., 2004; Horne et al., 2004).
Rare variants of NOTCH1, GATA5 and FBN1 were correlated with 4–
10%, 2.6% and one in eight BAV patients, respectively (Bonachea et al.,
2014; Garg et al., 2005; Padang et al., 2013; Pepe et al., 2014). Common
variants in FBN1 were also found to be associated with BAV/TAA
(LeMaire et al., 2011). Lack of knowledge of gene alterations predispos-
ing to majority of BAV/TAA patients has prevented the development of
mouse models. Due to the inaccessibility of appropriate cellular or
mouse model, so far, the mechanism of TAA in BAV patients remains
largely unknown.
Interestingly, the aortic root, ascending aorta, and aortic arch are
commonly involved in aneurysms, whereas the descending aorta is
rarely impacted in BAV/TAA (Fazel et al., 2008). Embryonic fate-map-
ping studies have demonstrated that the aortic root, ascending aortathe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
283J. Jiao et al. / EBioMedicine 10 (2016) 282–290and aortic arch are populated by SMCs arising from neural crest (NC),
while the descending aorta is populated by SMCs from the paraxial me-
soderm (PM) (Cheung et al., 2012;Majesky, 2007). Based on these facts,
we hypothesize that the aortopathy in BAV patients is due to a defective
differentiation of neural crest stem cells (NCSCs) to SMCs that spares the
paraxial mesoderm cells (PMCs)-derived SMCs. Advancement of in-
duced pluripotent stem cells (iPSCs) and lineage-speciﬁc SMCs differen-
tiation technology nowprovides uniquemethods to test this hypothesis
(Cheung et al., 2014).
2. Materials and Methods
2.1. Human Subjects
Clinical information about the subjects for iPSCs generation was
summarized in Fig. S1A. 5 to 10 ml of fresh blood was drawn from
each patient after written consents were obtained. PBMCs were har-
vested for reprogramming. This studywas approved by the Institutional
Review Board (IRB) at the University of Michigan Health System (Ann
Arbor, MI) in compliance with Health Insurance Portability and Ac-
countability Act (HIPAA) regulations and the Declaration of Helsinki.
All our study procedures were consistent with the IRB Guide for the
human subject studies.
2.2. iPS Cells Generation and Culture
The plasmids preparation and the procedure of non-integrated iPSC
derivation were performed according to the methods described previ-
ously (Su et al., 2013). In brief, PBMCs were separated from human pe-
ripheral blood, cultured and electrotransfected with non-integrating
DNA plasmids containing OCT4, SOX2, KLF4, and C-MYC. After the colo-
nies became compact at around day 30 post-infection, the colonies
were mechanically picked up from the culture dishes and cultured
with TesRE8 medium (Stemcells Inc.) on Matrigel (BD Corp.) coated
dishes. iPSCs were passaged every 4 to 6 days with Versene (Life Tech-
nologies Corp.). IPSCs at passages 25–35were used for the experiments.
2.3. Karyotype Analysis
The iPSCs were incubated in culture medium containing 0.25 μg/ml
colcemid (Invitrogen) for 2 h and were harvested and incubated in hy-
potonic solution containing 0.4% NaCl (Sigma Corp.) at 37 °C for 20min.
And cells were ﬁxed with a mixture of methanol:acetic acid (3:1, v/v).
Slides were aged for 8–12 h at 65 °C and digested with 0.8% trypsin
for 15–30 s. Slides were then stained with Giemsa (Gibco Corp.) for
10 min and air-dried.
2.4. NCSCs Differentiation From iPSCs
To differentiate iPSCs into NCSCs, iPSCs were dissociated with
Versene (Life Technologies Corp.) into single cells and seeded at
2 × 104 cells/cm2 with TesRE8 (Stemcells Inc.) medium supplemented
with Rocki (Y27632, Stemgent Inc.). When the cells reached a conﬂu-
ence of 40% to 60%,mediumwas changed into NCSC differentiationme-
dium, which contained DMEM/F12 (Life technologies Corp.), N2 (Life
technologies Corp.), Pen/Strep (Life technologies Corp.), Noggin (R&D
systems Corp.) at 200 ng/ml and SB431542 (Stemgent Inc.) at 10 μM.
NCSC differentiation medium was refreshed daily for 10 days.
2.5. PMCs Differentiation From iPSCs
To differentiate iPSCs into PMCs, iPSCs at 80–90% conﬂuence were
dissociated with Versene (Life technologies Corp.) and split (diluted in
freshmedium) at a ratio of 1:8 and seeded onMatrigel (BD Corp.) coat-
ed dishes with TesRE8 (Stemcells Inc.) medium supplemented with
Rocki (Y27632, Stemgent Inc.). When the cells reached 40% to 60%conﬂuence medium was changed into PMC differentiation medium,
which contained DMEM/F12 (Life technologies Corp.), N2 (Life technol-
ogies Corp.), Pen/Strep, FGF2 (20 ng/ml, R&D Systems Corp.), LY294002
(10 μM, Sigma Corp.), BMP4 (10 ng/ml, R&D Systems Corp.) for 1.5 days
then cultured in the above medium excluding BMP4 for 3.5 days
(Cheung et al., 2014).2.6. SMCs Differentiation From NCSCs
NCSCs were dissociated into single cells with Accutase (Life technol-
ogies Corp.) and sorted on HNK1 and P75 double positive using FACS
and seeded onto Matrigel (BD Corp.) coated dishes at a density of
4 × 104 cells/cm2 with medium containing DMEM/F12, N2, Pen/Strep
(Life technologies Corp.), EGF 10 ng/ml, FGF2 10 ng/ml (R&D systems
Corp.) and Rocki (Y27632, Stemgent Inc.). The medium was refreshed
on the second day with the same media without Rocki. At day 3, SMC
differentiation medium was applied which contained DMEM/F12,
15%KSR (Knockout Serum Replacement, Life technologies Corp.), and
Pen/Strep (Life technologies Corp.). TGFβ1 was added at 2 ng/ml to
the SMC differentiation medium in speciﬁc experimental groups. Medi-
um was refreshed daily for 9 days, changed into DMEM/F12, N2, Pen/
Strep (all from Life technologies). After two days, SMCs were treated
with rapamycin (20 nM, Millipore Corp.) or mock treated with DMSO
for two days until harvested for further analysis.2.7. SMCs Differentiation From PMCs
PMCs were dissociated into single cells with Accutase (Life technol-
ogies Corp.) and seeded onto Matrigel (BD Corp.) coated dishes with
density of 4 × 104 cells/cm2 with medium containing DMEM/F12,
15%KSR (Knockout Serum Replacement, Life technologies Corp.), Pen/
Strep (Life technologies Corp.), TGF-β1 2 ng/ml (R&D systems Corp.).
Medium was refreshed daily for 9 days then changed into DMEM/F12,
N2, Pen/Strep (all from Life technologies Corp.). Mediumwas refreshed
daily for four more days, SMCs were harvested for further analysis.2.8. Immunoﬂuorescence Staining and Flow Cytometry
Immunoﬂuorescence staining and ﬂow cytometrywas performed as
described (Jiao et al., 2013). The following primary antibodies were
used: anti-OCT4 (Santa Cruz Biotechnology Inc.), anti-SOX2 (Santa
Cruz Biotechnology Inc.), anti-NANOG (Cosmo Inc.), anti-HNK1
(Sigma Corp), anti-P75 (Advanced Targeting Systems Inc.), anti-TBX6
(Santa Cruz Biotechnology Inc.), anti-TCF15 (Santa Cruz Biotechnology
Inc.), anti-TAGLN (Abcam plc.), anti-MYH11 (Abcam plc.), anti-ACTA2
(Sigma Corp.), anti-CNN1 (Sigma Corp.). The following ﬂuorochrome-
conjugated secondary antibodies were used: Alexa Fluor 594 goat
anti-rabbit (Molecular Probes), Alexa Fluor 633 goat anti-mouse IgM
(Molecular Probes), Alexa Fluor 633 goat anti-mouse IgG (Molecular
Probes), and Alexa Fluor 633 rabbit anti-goat IgG (Molecular Probes).
Cells were applied to MoFlo Astrios or slides were mounted with anti-
fade mounting media containing DAPI (Prolonggold, Life technologies
Corp.). Stained cells were observed on a Nikon A1 confocal microscope.2.9. qPCR
Total RNA was puriﬁed with TRIzol Reagent (Life technologies,
Corp.). 1 μg of RNAwas reverse-transcribed usingM-MLVReverse Tran-
scriptase (Promega Corp.) and RNasein RNase Inhibitor (Promega
Corp.). QPCR was carried out with SYBR universal mix (BioRad Corp).
The primers were listed in Table S1. The expression level of genes in
each sample was normalized to GAPDH.
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Whole cell extracts were prepared using RIPA buffer, resolved on
SDS-PAGE gels, and transferred to acetate cellulose membranes. Prima-
ry antibodies used were anti-TAGLN (1:1000, Abcam plc.), anti-MYH11
(1:500, Abcam plc.), anti-ACTA2 (1:200, Sigma Corp.), anti-CNN1
(1:500, Sigma Corp.), anti-pSMAD2 (1:500, Cell Signaling Technology
Inc.), anti-pS6 (1:500, Cell Signaling Technology Inc.), anti-GAPDH
(1:2000, Santa Cruz Inc.). Secondary antibodies used were IRDye680RD
Donkey anti-Mouse, IRDye680LT Donkey anti-Rabbit, IRDye800CW
Donkey anti-Mouse, IRDye800CW Donkey anti-Rabbit (All secondary
antibodies were from Licor Inc.). Licor western blot detection system
was used for the dual-color imaging. ImageJwas used for the quantiﬁca-
tion of bands.
For the ELISA assay of the secreted TGF-β1, fresh medium (DMEM/
F12, N2, Pen/Strep, all from Life technologies Corp.) without serum
was applied to the cells and harvested after 24 h. ELISA assay was car-
ried out using the Human TGF-beta 1 Quantikine ELISA Kit from R&D
systems following the manufacture's guidelines.
2.11. Teratoma Formation
One million iPSCs were injected subcutaneously into each ﬂank of
the recipient nonobese diabetic/severe combined immunodeﬁcient
mice (NOD/SCID) mice (Jackson Laboratory, Bar Harbor, Maine). Paraf-
ﬁn sections and H&E staining of formalin-ﬁxed teratoma specimens iso-
lated from the mouse ﬂanks were prepared 3–5 weeks after injection.
2.12. Collagen Gel Assay
SMCs were suspended at 1 × 106 cells/ml in DMEM with type I col-
lagen (Cell Biolabs Inc.) at 2 mg/ml and NaOH (Cell Biolabs Inc.). The
mixture was poured into 24-well tissue culture plates (1 ml/well) and
allowed to gel in a 5% CO2 incubator at 37 °C for 30 min, and then
1 ml of medium (DMEM/F12, N2, Pen/Strep, all from Life technologies
Corp.) was added. After 3 days, gels were lifted and contraction was
assessed after 1 h by scanning the plates.
2.13. Carbachol Stimulated Contractility Assay
Differentiated SMC were washed with DMEM (Life technologies
Corp.) once and medium was replaced to DMEM with 1 mM carbachol
(Sigma Corp.). Cells were recorded every 1 min from 0 to 30 min
using a Nikon TE200 microscope with DP controller software. And the
pictures were condensed into a movie with DP controller software.
The cells were kept in the same places and the imaging parameters
were kept the same during the 30 min. Pictures at 0 and 30 min were
used to calculate the cell area reduction. Single cells were identiﬁed by
location and shape from pictures at 0 and 30 min. Cell surface areas
were measured using ImageJ software. Change of area of each cell
were normalized to its area at 0 min, and then normalized to the
mean value of normalized area reduction of cells from control patient.
3. Results
3.1. iPSCs Were Used to Model TAA Associated With BAV
iPSCs were derived from peripheral blood mononuclear cells
(PBMCs) using non-integrating DNA vectors with OCT4, SOX2, KLF4
and C-MYC (Okita et al., 2007; Su et al., 2013) from two patients (one
male 34 years old and one female 53 years old) with BAV, aneurysmal
ascending aorta and normal descending aorta, and one control male
65 years old patient with normal tricuspid aortic valve (TAV) and a
normal aorta (Figs. 1a, S1A). No mutation of NOTCH1 was found in
these patients by exome sequencing. The iPSC lines showed typical
morphology of human embryonic stem cells, maintained a normalkaryotype (Figs. 1b–c, S1C), expressed pluripotent markers, including
OCT4, NANOG, SOX2, SSEA4, TRA-1-60 and TRA-1-81 (Figs. 1d, S1B),
and formed teratomas in NOD/SCID mice (Figs. 1e, S1D). Based on
the correct karyotype, expression of pluripotent genes, and ability to
generate three germ layers in teratoma, two iPSCs lines from normal
control and two iPSCs lines from each BAV/TAA patient were selected
for differentiation experiments.
The iPSCs were differentiated into NCSCs by dual-SMAD inhibition
(Chambers et al., 2009). Typical neural rosette morphology was detect-
ed at days 10–12 (Figs. 1f, S1E). The NCSCs from BAV/TAA and control
iPSCs expressed the NCSCmarker genes SOX9, PAX3 and SLUG at similar
levels (Figs. 1g, S1F–H). Immunohistochemistry of the differentiated
NCSCs showed that N80% of the differentiated population expressed
cell membrane markers P75 and HNK1, indicating high differentiation
efﬁciency (Fig. 1h). N60% of differentiated cells were P75 and HNK1
double positive in ﬂow cytometry analysis, and double positive
cells were puriﬁed by ﬂow cytometry sorting for SMCs differentiation
(Fig. 1i).
3.2. SMCs Derived From BAV/TAA NCSCs Express Less MYH11 and Have
Impaired Contractile Function
We sought to determine if there were differences in the phenotype of
NCSC-SMCs from iPSCs derived from patients with BAV/TAA when com-
pared with control iPSCs. SMCs differentiated from the control NCSCs
gradually gained an enlarged and expanded morphology (Fig. 2a), and
showed increased expression level of SMCs markers (contractile protein
genes), includingMYH11, ACTA2, TAGLN, and CNN1 (Wang et al., 2003)
(Fig. S2A). Immunoﬂuorescence and Western blot analyses showed that
N90% of the cells were SMCs based on positive staining of corresponding
proteins, SMMHC, SMα-actin, SM22α and calponin-1 (Fig. 2a, c, e). Flow
cytometry showed that N70% of the differentiated cell population was
positive for the SMMHC, which is the most speciﬁc marker of SMCs
(Fig. S2B) (Owens et al., 2004). Functionally, the control SMCs could
contract in the collagen gel assay (Fig. 2g), and upon treatment with
carbachol (Fig. 2f, Movie S1). Therefore, mature contractile SMCs could
be efﬁciently differentiated from NCSCs.
The qPCR analysis and Western blotting assay of the SMCs from two
BAV/TAA-NCSCs showed signiﬁcantly lower expression of SMMHC
(Fig. 2b, c). In contrast SMα-actin, SM22α and calponin-1 were similarly
expressed between BAV/TAA and control samples (Fig. 2d–e). The carba-
chol assay and collagen gel contraction assay showed that the contraction
of BAV/TAA NCSC-SMCs decreased compared to control NCSC-SMCs
(Fig. 2f–g, i, Fig. S2C, Movies S1, S2). Importantly, primary culture of
SMCs explanted from the ascending aorta of BAV/TAA patients also
showed decreasedMYH11 expression in high through put sequencing of
mRNA, and impaired contraction when compared with SMCs explanted
from the normal aorta of heart transplant donors (Fig. 2h, j, Fig. S4A).
Interestingly, the NCSC-SMCs derived from iPSCs of BAV patient with
normal aorta showed levels of expression ofMYH11 similar to the control
(Fig. S2D). These results suggest that patientswith BAV/TAAhave a defect
in differentiating NCSC into fully contractile SMCs.
3.3. SMCs Derived From BAV/TAA PMCs Behave Similarly to the Control
SMCs
Since BAV/TAA patients rarely develop aneurysms in other segments
of the aorta, we sought to determine if the PMC-derived SMCs from
these patients also showed defective contractile function. QPCR
analyses showed signiﬁcant elevation of expression levels of the PMCs
marker genes, MEOX1, TBX6 and PAX1, in the control and BAV/TAA
differentiated PMCs from iPSCs (Fig. 3a). The majority (N80%) of the
BAV/TAA and control differentiated PMCs were positive for paraxial
mesoderm markers TCF15 and TBX6 in immunoﬂuorescence staining
assay (Fig. 3b, c).
Fig. 1. iPSCs from BAV/TAA patient are pluripotent and can differentiate to NCSCs. (a) 3-D reconstruction of a Computed Tomography (CT) scan of the aorta in a BAV/TAA patient. (b)
Morphology of PBMCs and iPSCs from BAV/TAA. (c) Karyotyping of iPSCs from BAV/TAA. (d) Immunostaining of OCT4, SOX2, NANOG, SSEA4, TRA-1-60 and TRA-1-81 in the BAV/TAA
iPSC colonies. The scale bars represent 50 μm. (e) H&E staining of teratomas derived from the BAV/TAA iPSCs injected into the ﬂanks of NOD/SCID mice. The scale bars represent
50 μm. (f) Morphological change of NCSCs from day 0 to day 10 in cell culture. The scale bars represent 500 μm. (g) Relative gene expression of NCSC marker genes SLUG, SOX9, PAX3
in iPSCs, NCSCs and PMCs assessed by quantitative PCR (qPCR). Each group contains two cell lines. Experiments were repeated three times. (h) Immunoﬂuorescence staining of NCSC
markers HNK1 and P75 of the NCSCs. The scale bars represent 100 μm. (i) Flow cytometry of HNK1 and P75 of the NCSCs. PBMCs: peripheral blood mononuclear cell. iPSCs: induced
pluripotent stem cells. NCSCs: neural crest stem cells. PMCs: paraxial mesoderm cells. H&E: hematoxylin and eosin. BAV/TAA: bicuspid aortic valve/ thoracic aortic aneurysm. Ctrl:
Control. Data is represented as mean ± SEM. See also Fig. S1.
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Fig. 2. BAV/TAA SMCsderived fromNCSCs havedecreased expression ofMYH11 and impaired contractile activity. (a) Immunoﬂuorescence staining cells for SMMHC, SMα-actin, calponin-
1 and SM22α. The scale bars represent 100 μm. (b)Western blot analysis of SMMHC in SMCs derived from BAV/TAA and control NCSCs. Lower panel: quantiﬁcation of western blot data.
(c) Relative expression of MYH11 in SMCs by qPCR. (d) Relative gene expression of the indicated SMC makers. (e) Western blot of SM α-actin, SM22α, calponin-1 and GAPDH. (f)
Quantiﬁcation of reduction of cell surface areas after treatment with carbachol. (g–h) Representative collagen gel assay. (i–j) Quantiﬁcation of gel area reduction in the collagen gel
assay in (G) and (H), respectively. n = 3 in each group. Ctrl: control. Data is represented as mean ± SEM. Results were normalized to control. In (c), (d), (f), and (i), each group
contains two cell lines. Experiments were repeated three times.*: P b 0.05. **: P b 0.01. See also Fig. S2.
286 J. Jiao et al. / EBioMedicine 10 (2016) 282–290The SMCs from BAV/TAA and control PMCs had upregulated expres-
sion level of SMCs marker genesMYH11, ACTA2, CNN1 and TAGLN (Fig.
3d), and N90% of the SMCs were positive for calponin-1 and SM22α in
the immunoﬂuorescence staining assay (Fig. 3e, f). The expression
level of CNN1 was slightly higher in the BAV/TAA SMCs derived from
PMCs when compared to the control (Fig. 3d). And PMC-SMCs in both
BAV/TAA and control expressed more MYH11 than their counterparts
of NCSC-SMCs (Fig. S3F). Western blot assay also conﬁrmed that
SMMHC, SM α-actin, SM22α and calponin-1 were similar in protein
levels in SMCs from BAV/TAA PMCs and control PMCs (Figs. 3g, S3A–
D). Furthermore, with carbachol treatment, the relative change of cell
surface area was comparable between SMCs derived from BAV/TAA
PMCs and control PMCs (Figs. 3h, S3E, Movies S4, S5). These results in-
dicated that the SMCs from BAV PMCs were as fully differentiated and
contractile as those derived from control PMCs.3.4. SMCs Derived From BAV/TAA NCSCs Have Decreased TGF-β Pathway
Signaling and Increased mTOR Signaling, and Inhibition of mTOR Signaling
by Rapamycin Rescues the Impaired Contraction Phenotype
To characterize the phenotype of aortic SMCs from BAV/TAA pa-
tients, whole transcriptome sequencing of the mRNAs from SMCs
explanted from the ascending aorta of one BAV/TAA and three heart
transplant donors as control was performed, which showed more than
one hundred differentially expressed genes. A portion of those genes
were enriched in TGF-β signaling pathway, mTOR signaling pathway
and PDGF signaling pathway (Fig. S4A). We found that the relative
gene expression of TGF-β1 ligand and TGF-β2 ligand were similar in
BAV/TAA NCSC derived SMCs (Fig. S4B–D). TGF-β receptor 1 and 2
mRNA was found to be decreased in BAV/TAA (Fig. S4E, F). Relatedly,
phosphorylated SMAD2 (pSMAD2) signiﬁcantly decreased in BAV/TAA
Fig. 3. Contractile function is comparable to control in SMCs derived from BAV/TAA PMCs. (a) Relative expression level of PMCmarker genesMEOX1, TBX6 and PAX1 evaluated using qPCR.
(b and c) Immunoﬂuorescence staining of TBX6 and TCF15 of PMCs. The scale bars represent 50 μm. (d) Relative expression level of SMCs marker genes evaluated using qPCR. (e and f)
Immunoﬂuorescence staining of SMC markers. (g) Immunoblotting of SMMHC, SM α-actin, SM22α, calponin-1 and GAPDH. (h) Quantiﬁcation of reduction of cell surface area after
stimulation by carbachol. Ctrl: control. PMCs: paraxial mesoderm cells. Data is represented as mean ± SEM. Results were normalized to control. In (a), (d), and (h), each group
contains two cell lines. Experiments were repeated three times. **: P b 0.01. *: P b 0.05. See also Fig. S3.
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factor (CTGF) expression level in the BAV/TAA group was signiﬁcantly
lower than in controls (Fig. 4d). Previous studies showed that TGF-β
regulates expression of Myocardin (MYOCD), an important transcrip-
tion factor regulating expression of MYH11 (Davis-Dusenbery et al.,
2011). Here, we found thatMYOCD expression signiﬁcantly decreased
in the BAV/TAA patients NCSC-derived SMCs (Fig. 4e).
We also found more phosphorylated S6 (pS6) protein levels in pa-
tients' SMCs when compared with the control, indicating hyperactive
mTOR signaling pathway (Fig. 4a, c). Rapamycin inhibits mTOR signal-
ing, thus promotes SMC differentiation through Akt2 activation
(Martin et al., 2007). Levels of phosphorylated S6 decreased with
rapamycin treatment the patients' cells (Fig. 4h, i, k, l). Treatment of
20 nM rapamycin for two days restored the expression of MYH11 and
SMMHC in BAVNCSC-SMCs (Fig. 4f–h, k, j, m) and rescued the impaired
contractile function of the BAV/TAA NCSC derived SMCs (Fig. 4n, o,
Movies S2, S3). Interestingly, TGF-β signaling related genes and
MYOCD expression level did not decrease in BAV/TAA PMC-SMCs
(Fig. S4G).
4. Discussion
The thoracic aortic aneurysm in BAV patients frequently involves as-
cending aorta, where the SMCs are derived from the neural crest. In con-
trast, patients with BAV rarely have aneurysms involving thedescending thoracic aorta, and the SMCs in this region of the aorta are
derived from paraxial mesoderm (Cheung et al., 2014; Cheung et al.,
2012; Fazel et al., 2008; Gillis et al., 2013). In this study, we found de-
creased MYH11 expression of NCSCs to SMCs in patients with BAV/
TAA using an iPSC modeling system. Notably, PMCs derived SMCs
from the same patients' iPSCs did not demonstrate these differences,
suggesting that the underlying defect leading to decreased expression
of SMMHC and contractile function is speciﬁc for NCSC-derived SMCs.
A speciﬁc altered NCSC behavior was considered to cause a speciﬁc
type of BAV, namely, Sievers type 1 (Sievers and Schmidtke, 2007)
with left coronary cusp (LCC) and right coronary cusp (RCC) fusion
(Fazel et al., 2008). We hypothesized that in this speciﬁc subtype of
BAV, NCSCs play an important role in the pathogenesis of the ascending
aortic aneurysm.We tested this with iPSCs from two unrelated patients
with BAV (Sievers type 1, LCC-RCC fusion) and ascending aortic aneu-
rysm and differentiated them into NCSCs (Fig. 1), then into SMCs
(Fig. 2) and studied the phenotype of these SMCs.
This unique approach using patients' iPSCs as a model system is a
unique approach to study BAV/TAA from stem cells to somatic cells
without directly involving human tissue. These results cannot be ob-
tained from studying the aortic aneurysmal tissue harvested during sur-
gery from BAV/TAA patients for multiple reasons. First, the aortic SMCs
would be explanted from the end stage aortic aneurysm, and it has been
previously shown that the disease process leads to epigenetic changes
in the SMCs (Prakash et al., 2014). Second, it would not be ethical to
Fig. 4. SMCs derived fromBAV/TAANCSCswere impaired TGF-β signal pathway and had hyperactivemTORpathway; inhibition ofmTORpathway by rapamycin could rescue impairment
of contractile function of BAV/TAA SMCs. (a) Immunoblotting of pSMAD2, pS6, S6 and GAPDH. (b and c) Quantiﬁcation of pS6 and pSMAD2 of (A) bymeasuring signal intensity. (d and e)
Relative expression of CTGF andMYOCD in qPCR. (f and g) Relative expression ofMYH11 using qPCR in SMCs derived from BAV/TAA NCSCs treatedwith 20 nM rapamycin ormock treated
withDMSO for 2 days. (h and k) Immunoblotting of SMMHC, pS6 andGAPDH.Mockmeans treatedwithDMSO, the solvent of rapamycin. (i, j, l,m)Quantiﬁcation of pS6 and SMMHCof (h)
and (k) respectively bymeasuring signal intensity. (n and o)Quantiﬁcation of reduction of cell surface area after stimulation by carbachol. Ctrl: control. Data is represented asmean±SEM.
Results were normalized to control. In (b–o), each group contains two cell lines. Experiments were repeated three times. * indicates P b 0.05. ** indicates P b 0.01. See also Supplementary
Fig. S4.
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tissue solely for research purposes. We can differentiate iPSCs into dif-
ferent lineages to model ascending aorta with NCSCs and descending
thoracic aorta with PM, and study the difference of the SMCs from
those two different lineages. Differentiation efﬁciency of iPSCs to
NCSCs was above 60%. Flow cytometry was applied to purify the
NCSCs population due to relatively low efﬁciency. More investigation
is needed to improve the NCSCs differentiation method. Finally, this
iPSC approach also avoids other confounding factors that may cloud
themechanistic study of aortopathy in BAV patients when one uses aor-
tic tissue, such as the function of aortic valve, hemodynamics, sites of
sampling, mixture of the subtypes of BAV, and size of the aorta.
As we hypothesized, the SMCs derived from BAV/TAA NCSCs were
less mature with lower levels of SMMHC and decreased contractile
function when compared to control NCSC-SMCs. In contrast, the BAV/
TAA SMCs derived from PM showed preserved differentiation, matura-
tion and contractile function. This was consistent with the patients' CT
ﬁndings of ascending aortic aneurysm but normal descending thoracic
aorta. The decreased contractile function in the BAV/TAA NCSC-SMCs
was also consistent with the poor contractile function in primary cul-
tured SMCs from the aneurysmal ascending aorta from the BAV/TAA pa-
tients. With the decreased expression of MYH11 and abnormal
contractile properties, one can speculate that the ascending aortaconsisted of poorly contractile NCSC-derived SMCs gradually develops
into an aneurysm under either normal blood pressure or hypertension,
and abnormal hemodynamics due to BAV. Indeed, immature SMCs and
a loss of their contractile-phenotype were also found in the dilated as-
cending aorta in BAV patients (Fernandez et al., 2009; Grewal et al.,
2014b). SMMHC is necessary to maintain SMC contractile function
(Kuang et al., 2012). Patients with MYH11 mutations are also
predisposed to TAA and dissection (Forte et al., 2013; Kuang et al.,
2011; Kuang et al., 2012; Zhu et al., 2006). It was not surprising to see
that SMCs with decreased expression of MYH11 had poor contractile
function and this phenotype ultimately contributes to the aortopathy
of ascending aorta, and development of aortic aneurysm. A series of
genes have been identiﬁed, MYH11, ACTA2, MYLK, that when mutated
cause thoracic aortic aneurysms and dissections (Gillis et al., 2013).
The mutations in these genes have been shown or are predicted to
lead to decrease SMC contraction (Humphrey et al., 2015). Additionally,
when the genes disrupted by unique copy number variants in patients
with thoracic aortic disease were analyzed at to what cellular process
theywere part of, these geneswere predicted to disrupt smoothmuscle
adhesion or contraction (Prakash et al., 2014).
TGF-β signaling is critical for differentiation and survival of SMCs
from NCSCs and for maintaining the contractile phenotype late in
life (Humphrey et al., 2014; Mao et al., 2012; Xie et al., 2013). In
289J. Jiao et al. / EBioMedicine 10 (2016) 282–290NCSCs, p-Smad2 interacts with the myocardin-related transcription
factor to regulate SMC marker gene expression. Deletion of Smad2
results in defective differentiation of NC cells into vascular SMCs in
aortic arch arteries (Xie et al., 2013). TGF-β upregulatesMYOCD expres-
sion, which is a master regulator of the expression of smooth muscle
marker genes, includingMYH11 (Davis-Dusenbery et al., 2011; Wang et
al., 2003). In the SMCs derived from BAV-NCSCs, the signaling of the
TGF-β canonical pathway signiﬁcantly decreased as manifested by de-
creased pSMAD2 and CTGF. MYOCD expression levels were also down-
regulated. The decreased TGF-β signaling could impair the expression
of MYOCD and thus down regulate SMC marker gene expression, in-
cluding MYH11. Interestingly, two groups have reported separately
that impaired canonical TGF-β signaling was also found in the ascending
aortic tissue in BAV patients, and might potentiate the development of
aneurysms in BAV (Grewal et al., 2014a; Paloschi et al., 2015). Our in
vitromodel provided another piece of evidence that defective TGF-β sig-
naling might be the cause of the defective differentiation of NCSCs and
the observed aortopathy in the BAV patients with ascending aortic
aneurysm.
On the other hand, impairment of the TGF-β pathway in SMCs re-
sulted in hyperactive mTOR pathway and caused aneurysms in a SMCs
conditional Tgfbr2 knockout mouse model, and rapamycin administra-
tion prevented aortic dilation (Li et al., 2014). In a Tsc2 knockout
mouse model, elevated mTOR signaling decreased expression of SMCs
contractile genes, and rapamycin promoted SMC contractile gene ex-
pression and prevented aneurysms (Cao et al., 2010). SMC differentia-
tion is promoted by activating phosphatidylinositol 3-kinase (PI3K)
and Akt which are negatively regulated by mTOR and S6 kinase 1
(S6K1). Rapamycin promotes SMC differentiation by inhibiting mTOR,
S6K1 and activating Akt2 (Martin et al., 2007). In the BAV/TAA NCSC
SMCs, we also found upregulation of phosphorylated S6, indicating up-
regulation of the mTOR pathway, which may also contribute to the
downregulation of the contractile gene SMMHC expression. Also, the
ﬁnding that rapamycin promotes MYH11 expression and contractile
function in the BAV/TAA patient derived NCSC-derived SMCs raises
the possibility that rapamycin might be a potent therapeutic drug for
BAV associated aneurysms.
There is limitation of this study.We only used two BAV/TAA patients
and one control with two different iPS cell lines for each subjects. How-
ever, these studies provide unique insights of aortopathy in BAV/TAA
patients, which cannot be obtained from any othermodels. Future stud-
ies can validate and expand these results.
In conclusion, in the patients with BAV (Sievers type 1, LCC-RCC fu-
sion) and TAA, the decreased contractile function identiﬁed in NCSCs-
derived SMCsmay contribute to the aortopathy and development of as-
cending aortic aneurysms. These studies demonstrate theutility of iPSCs
in deﬁning the molecular basis of a disease process without knowing
the underlying genetic defect responsible for observed abnormality.
Using this system, we could demonstrate a clear contractile defect in
the NCSC-derived SMCs that was not present in the PM-derived SMCs.
Finally, our results add to the accumulating data that decreased SMC
contractile function predisposes to thoracic aortic disease.
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